

ITL Wins SSK Contract Extension with US Blood Bank

ITL BioMedical, a division of ITL Health Group (ASX: ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce a contract extension of 12 months with a large US community blood bank for its SampLok Sampling Kit (“SSK”). ITL BioMedical has been a supplier to this blood center for over four years.

ITL BioMedical is a growing provider of specialty ancillary products for the blood culture testing market, estimated to be worth US\$3.3b in 2016 and growing to US\$4.8b by 2021⁽¹⁾. SSK is a highly innovative product that is utilized in the blood banking market to transfer platelet samples during bacterial detection testing. It offers state of the art product design that facilitates product sampling for laboratory testing process efficiencies, safety in reducing potential for needlestick injuries and reduced biohazard waste, among other benefits.

This contract extension is in line with ITL’s ongoing strategy to maintain strong sales of SSK in the US whilst reaching new global markets. ITL announced on 13th July that the largest South America Blood Center, Pro Sanguine, has started using SSK. Within the last 18 months SSK has been implemented by One Blood, a major US blood bank, several Taiwan Blood Centers, and a New Zealand Blood Center.

Stephanie Norrell, Vice President, Sales and Marketing at ITL BioMedical commented “We are very pleased that the Blood Center has extended our long-standing contract. Our extended relationship is validation of the continued relevance of the advantages SSK.”

Bill Mobbs, Executive Chairman of ITL Health Group said “The extension of the contract with the US community blood bank, who are forecasting year on year growth, reconfirms the clients support and our unique positioning of SSK. We expect this will also pave the way for further successes throughout the year with other Blood Banks.”

Bill Mobbs
Executive Chairman

About ITL BioMedical – ITLBioMedical.com

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division’s patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide.

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au